Baidu
map

Ann Rheum Dis:银屑病关节炎患者关节和皮肤改善对健康相关生存质量的影响

2019-05-23 xiangting MedSci原创

患者HRQoL的最佳改善取决于成功治疗关节和皮肤症状。

这项研究旨在确定银屑病关节炎(PsA)患者中关节和皮肤改善对健康相关生存质量(HRQoL)的影响。

SPIRIT-P1和SPIRIT-P2是研究ixekizumab的3期试验,ixekizumab是一种白介素-17A拮抗剂,用于治疗活动性PsA。患者被随机分为ixekizumab组或安慰剂组。结局包括银屑病关节炎疾病活动性指数(DAPSA)、银屑病面积和严重程度指数(PASI)、欧洲五维生活质量(EQ-5D)视觉模拟评分(VAS)、36项简表健康调查(SF-36)和工作生产力与活动受损(WPAI)调查问卷。关节和皮肤改善对HRQoL的贡献使用平滑样条方法建模,并用响应面图形描绘。

在该综合分析中,402例PsA患者基线银屑病≥3%的体表面积。对该患者数据集应用了响应面建模,以调查第24周时DAPSA、PASI和HRQoL改善之间的关联。EQ-5D VAS的最大改善与DAPSA和PASI最大百分比的改善相关,而不仅仅是DAPSA或PASI。对SF-36和WPAI也进行了类似观察。

患者HRQoL的最佳改善取决于成功治疗关节和皮肤症状。

原始出处:

Arthur Kavanaugh. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 21 May 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1749059, encodeId=7b481e4905997, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Thu Aug 29 14:01:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815022, encodeId=113218150226b, content=<a href='/topic/show?id=f0959663657' target=_blank style='color:#2F92EE;'>#银屑病关节炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96636, encryptionId=f0959663657, topicName=银屑病关节炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Oct 04 04:01:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013014, encodeId=a9f120130140d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Nov 07 11:01:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265974, encodeId=1cb912659e4d3, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 25 03:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1749059, encodeId=7b481e4905997, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Thu Aug 29 14:01:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815022, encodeId=113218150226b, content=<a href='/topic/show?id=f0959663657' target=_blank style='color:#2F92EE;'>#银屑病关节炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96636, encryptionId=f0959663657, topicName=银屑病关节炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Oct 04 04:01:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013014, encodeId=a9f120130140d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Nov 07 11:01:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265974, encodeId=1cb912659e4d3, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 25 03:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1749059, encodeId=7b481e4905997, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Thu Aug 29 14:01:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815022, encodeId=113218150226b, content=<a href='/topic/show?id=f0959663657' target=_blank style='color:#2F92EE;'>#银屑病关节炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96636, encryptionId=f0959663657, topicName=银屑病关节炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Oct 04 04:01:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013014, encodeId=a9f120130140d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Nov 07 11:01:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265974, encodeId=1cb912659e4d3, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 25 03:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1749059, encodeId=7b481e4905997, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Thu Aug 29 14:01:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815022, encodeId=113218150226b, content=<a href='/topic/show?id=f0959663657' target=_blank style='color:#2F92EE;'>#银屑病关节炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96636, encryptionId=f0959663657, topicName=银屑病关节炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Oct 04 04:01:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013014, encodeId=a9f120130140d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Nov 07 11:01:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265974, encodeId=1cb912659e4d3, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 25 03:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 lmm397

相关资讯

Arthritis Rheumatol:乌司奴单抗降低银屑病关节炎血清CRP、IL-17A和IL-17F水平

基线血清IL-23/-17水平与皮肤疾病活动性相关,而不是关节,表明存在组织特异性差异。

Semin Arthritis Rheu:银屑病关节炎疾病影响问卷的新作用

最小疾病活动度(MDA)使用健康评估问卷(HAQ)作为一个标准。随着PsA病程的增加,HAQ与疾病活动性的相关性不佳,并且其在MDA中的应用受到质疑。银屑病关节炎疾病影响(PsAID)是专为PsA患者开发的。这项研究目的是在患者队列中验证PsAID,并确定在MDA中PsAID是否可以取代HAQ。从PsA诊所招募患者,并根据标准方案进行评估,其中包括人口学、临床特征和实验室检查。进行描述性统计。基于

J Rheumatol:银屑病关节炎患者的负担和疾病特征

不同严重程度PsA患者的疾病负担都很明显。相当一部分PsA患者未接受过抗银屑病治疗。

Ann Rheum Dis:早期使用TNF抑制剂有助于银屑病关节炎的缓解

在早期PsA患者中,第22周戈利木单抗+MTX的DAS缓解率几乎是单用MTX的2倍。

J Rheumatol:使用生物制剂治疗银屑病关节炎的指炎和附着点炎

汇总分析表明,抗TNF-α药物与新型药物(ustekinumab、苏金单抗和ixekizumab)在指炎和附着点炎上具有相同疗效。

Baidu
map
Baidu
map
Baidu
map